Kiniksa Pharmaceuticals, Ltd. (KNSA)
Automate Your Wheel Strategy on KNSA
With Tiblio's Option Bot, you can configure your own wheel strategy including KNSA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KNSA
- Rev/Share 8.124
- Book/Share 7.2737
- PB 6.5153
- Debt/Equity 0.0182
- CurrentRatio 3.8476
- ROIC 0.0477
- MktCap 3473212389.0
- FreeCF/Share 1.3821
- PFCF 34.1405
- PE 97.1149
- Debt/Assets 0.0136
- DivYield 0
- ROE 0.0746
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | KNSA | Canaccord Genuity | -- | Buy | -- | $62 | Feb. 19, 2026 |
| Initiation | KNSA | TD Cowen | -- | Buy | -- | $60 | Sept. 29, 2025 |
| Initiation | KNSA | Citigroup | -- | Buy | -- | $40 | March 13, 2025 |
| Initiation | KNSA | Jefferies | -- | Buy | -- | $40 | Sept. 13, 2024 |
News
Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock
Published: March 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Kiniksa Pharmaceuticals (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
Wall Street Analysts See a 73.42% Upside in Kiniksa Pharmaceuticals (KNSA): Can the Stock Really Move This High?
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 73.4% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
LONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 25, 2025 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2024 financial results and recent portfolio execution.
Read More
About Kiniksa Pharmaceuticals, Ltd. (KNSA)
- IPO Date 2018-05-25
- Website https://www.kiniksa.com
- Industry Biotechnology
- CEO Sanj K. Patel
- Employees 315